Information  X 
Enter a valid email address

Feedback PLC (FDBK)

  Print          Annual reports

Thursday 06 May, 2021

Feedback PLC

Executive Appointment

RNS Number : 6229X
Feedback PLC
06 May 2021

Reach announcement


Feedback plc


Anesh Patel appointed as CFO of Feedback Medical


Lindsay Melvin, CFO of Feedback PLC set to retire in H2 2021, succession planning underway


London, 6 May 2021 Feedback plc (AIM: FDBK, "Feedback" or the "Company"), the specialist medical imaging technology company, is pleased to announce the appointment of Anesh Patel as Chief Financial Officer of its trading subsidiary, Feedback Medical Limited, with immediate effect.


Anesh is joining the Group as part of a succession planning programme following Lindsay Melvin's (Chief Financial Officer of Feedback) decision to retire during H2 2021. Anesh will work alongside Lindsay in the coming months to ensure a smooth and orderly transition.


Anesh Patel joins Feedback Medical from hVIVO Limited, a subsidiary of AIM-listed Open Orphan plc and a rapidly growing, industry-leading, clinical services provider to pharma, biotech and government organisations where most recently he was finance & corporate projects director.  Prior to hVIVO, he spent seven years in investment banking where he specialised in corporate finance advisory services, at leading banks including Société Générale and Standard Bank.  Anesh started his professional career with Ernst & Young in 2004 where he qualified as a chartered accountant, initially working within the audit & assurance division before transferring to the transaction advisory services - transaction support team for private equity clients. He graduated from University College London (UCL) and holds an MSci. (Hons) degree in Mathematics with Economics.


Rory Shaw, Chairman of Feedback, commented: "We are delighted to welcome Anesh to the Group. He brings a wealth of wide-ranging corporate and commercial finance experience and will provide a safe pair of hands as we begin the process of succession planning following Lindsay's notice of retirement.  Lindsay will be very much missed, but we believe that in the coming months, together they will set the Company in good shape to build its future - based on the Company's flagship clinical communications platform, Bleepa."






Feedback plc

Rory Shaw, Chairman

+44 (0) 20 3997 7634

[email protected]



Allenby Capital Limited (Nominated Adviser)

David Worlidge / David Hart

+44 (0)20 3328 5656



Walbrook PR Ltd

Tel: 020 7933 8780 or [email protected]

Paul McManus/Nick Rome/Nicholas Johnson

07980 541 893 or 07748 325 236 or 07884 664 686



Notes to editors


Feedback plc (AIM: FDBK) is a medical imaging technology business. Its core product, Bleepa, is a revolutionary medical imaging communications app, providing an easy-to-use, high quality tool to enable remote and secure communications between front-line clinicians and teams. Importantly, it is the only CE marked medical imaging communications platform on the NHSx clinical communications tools framework. Bleepa has unparalleled functionality for everyday practice and can be accessed from any internet-connected device, enabling control of patient cases when on the go. 


Its highly scalable Software as a Service ("SaaS") based revenue model will provide increasing levels of visibility as the Company grows its customer base. With a growing distribution base and technology in place, the focus is on leveraging key relationships in order to drive sales both in the UK and internationally to all forms of care facilitators. As a fully certified medical device, Bleepa aims to disrupt the medical imaging communications market and, importantly, increase the accuracy and speed of diagnosis.


About Reach announcements

This is a Reach announcement. Reach is an investor communication service aimed at assisting listed and unlisted (including AIM quoted) companies to distribute non-regulatory news releases into the public domain. Information required to be notified under the AIM Rules for Companies, Market Abuse Regulation or other regulation would be disseminated as an RNS regulatory announcement and not on Reach.

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

a d v e r t i s e m e n t